Live virus vaccines in human immunodeficiency virus-infected children: a retrospective survey. 1988

M McLaughlin, and P Thomas, and I Onorato, and A Rubinstein, and J Oleske, and S Nicholas, and K Krasinski, and P Guigli, and W Orenstein
New York City Department of Health, Division of Medical Affairs, NY 10013.

Live virus vaccines can cause serious adverse reactions when administered to immunocompromised patients. Because children infected with human immunodeficiency virus (HIV) may be immunosuppressed, immunization of these children with live virus vaccines is a potential problem. A retrospective survey was conducted by the New York City Department of Health, with consultation from the Centers for Disease Control, to evaluate the frequency of serious adverse events following receipt of live vaccines among children with HIV infection receiving pediatric care in New York City and New Jersey. Outpatient records of 319 children being cared for by 16 participating physicians were reviewed. Of the 319 charts, 221 (69%) contained vaccination histories. Perinatal transmission of HIV infection was suspected for 208 (94%) of the 221 cases and infection via transfusion for the remaining 13 (6%). Of the 221 for whom immunization histories were available, 180 (81%) had received at least one dose of live oral polio vaccine and 70 (32%) had received measles, mumps, and rubella vaccine. There were 120 children for whom a temporal relationship between immunization and onset of symptoms of immunodeficiency could be seen; 46/120 had received at least one dose of oral polio vaccine and 23/45 had received measles, mumps, and rubella vaccine after onset of symptoms. Although follow-up of this population has been limited, there were no reports of serious adverse events such as typical or atypical measles, paralytic poliomyelitis, or aseptic meningitis in the month following vaccination.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008458 Measles Vaccine A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed) Vaccine, Measles
D009108 Mumps Vaccine Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine. Inactivated Mumps Vaccine,Inactivated Mumps Virus Vaccine,Live Attenuated Mumps Vaccine,Live Attenuated Mumps Virus Vaccine,Mumps Vaccine, Inactivated,Mumps Vaccine, Live Attenuated,Mumps Virus Vaccine, Inactivated,Mumps Virus Vaccine, Live Attenuated,Vaccine, Inactivated Mumps,Vaccine, Mumps
D011055 Poliovirus Vaccine, Oral A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed) Sabin Vaccine,Oral Poliovirus Vaccine,Vaccine, Oral Poliovirus,Vaccine, Sabin
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

M McLaughlin, and P Thomas, and I Onorato, and A Rubinstein, and J Oleske, and S Nicholas, and K Krasinski, and P Guigli, and W Orenstein
January 1998, Journal of the National Cancer Institute. Monographs,
M McLaughlin, and P Thomas, and I Onorato, and A Rubinstein, and J Oleske, and S Nicholas, and K Krasinski, and P Guigli, and W Orenstein
September 1996, The Pediatric infectious disease journal,
M McLaughlin, and P Thomas, and I Onorato, and A Rubinstein, and J Oleske, and S Nicholas, and K Krasinski, and P Guigli, and W Orenstein
April 2011, The Pediatric infectious disease journal,
M McLaughlin, and P Thomas, and I Onorato, and A Rubinstein, and J Oleske, and S Nicholas, and K Krasinski, and P Guigli, and W Orenstein
January 2016, Journal of the International AIDS Society,
M McLaughlin, and P Thomas, and I Onorato, and A Rubinstein, and J Oleske, and S Nicholas, and K Krasinski, and P Guigli, and W Orenstein
January 2008, Journal of the cardiometabolic syndrome,
M McLaughlin, and P Thomas, and I Onorato, and A Rubinstein, and J Oleske, and S Nicholas, and K Krasinski, and P Guigli, and W Orenstein
January 1991, The Journal of pediatrics,
M McLaughlin, and P Thomas, and I Onorato, and A Rubinstein, and J Oleske, and S Nicholas, and K Krasinski, and P Guigli, and W Orenstein
September 2014, Endocrinology and metabolism clinics of North America,
M McLaughlin, and P Thomas, and I Onorato, and A Rubinstein, and J Oleske, and S Nicholas, and K Krasinski, and P Guigli, and W Orenstein
April 2005, The Pediatric infectious disease journal,
M McLaughlin, and P Thomas, and I Onorato, and A Rubinstein, and J Oleske, and S Nicholas, and K Krasinski, and P Guigli, and W Orenstein
April 1997, The Pediatric infectious disease journal,
M McLaughlin, and P Thomas, and I Onorato, and A Rubinstein, and J Oleske, and S Nicholas, and K Krasinski, and P Guigli, and W Orenstein
August 1996, Pediatric AIDS and HIV infection,
Copied contents to your clipboard!